Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2018

  • ID: 4518495
  • Report
  • 111 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • ArQule Inc
  • Bristol-Myers Squibb Co
  • Exelixis Inc
  • Merck KGaA
  • Millendo Therapeutics Inc
  • MORE
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2018, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline landscape.

Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female, hereditary disease that affects the adrenal glands, age and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females and deepened voice in females.

Report Highlights:

This latest pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • ArQule Inc
  • Bristol-Myers Squibb Co
  • Exelixis Inc
  • Merck KGaA
  • Millendo Therapeutics Inc
  • MORE
Introduction

Report Coverage

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development

AbbVie Inc

ArQule Inc

Bristol-Myers Squibb Co

Exelixis Inc

Infinity Pharmaceuticals Inc

Merck KGaA

Millendo Therapeutics Inc

Orphagen Pharmaceuticals Inc

Trovagene Inc

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drug Profiles

8H-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABBV-176 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avelumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabozantinib s-malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

derazantinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPI-549 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipilimumab + nivolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nevanimibe hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCM-075 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize SF-1 for Cushing's Syndrome, Endometriosis and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones

Featured News & Press Releases

Jan 08, 2018: Infinity Provides Update on IPI-549 Phase I/Ib Study, 2018 Goals and Financial Guidance

Nov 10, 2017: Infinity Pharmaceuticals Reports IPI-549 Clinical and Translational Data from Completed Monotherapy Dose-Escalation Component of Phase 1/1b Clinical Study in Patients with Advanced Solid Tumors at SITC Annual Meeting

Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing's Syndrome

Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2

Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2

Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers

Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by AbbVie Inc, H1 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by ArQule Inc, H1 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Bristol-Myers Squibb Co, H1 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Exelixis Inc, H1 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Infinity Pharmaceuticals Inc, H1 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, H1 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Millendo Therapeutics Inc, H1 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals Inc, H1 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Trovagene Inc, H1 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H1 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • ArQule Inc
  • Bristol-Myers Squibb Co
  • Exelixis Inc
  • Infinity Pharmaceuticals Inc
  • Merck KGaA
  • Millendo Therapeutics Inc
  • Orphagen Pharmaceuticals Inc
  • Trovagene Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll